This open-label, multi-center Phase 2 study is designed to evaluate the safety and efficacy of VGX-3100 administered Inovio's CELLECTRA delivery system in adult men and women with anal HSIL
caused by HPV-16 and/or HPV-18 and builds on significant clinical benefits demonstrated with Inovio's HPV immunotherapies in multiple clinical trials.
MONDAY, July 22, 2019 (HealthDay News) -- The prevalence of anal high-grade squamous intraepithelial lesions (HSILs
), which precede anal cancer, is high among women living with HIV (WLHIV) in the United States, according to a study published online July 11 in Clinical Infectious Diseases.
(53,54) Similar to HSIL
, bowenoid papulosis is associated with high-risk HPV, particularly HPV 16.
* High-Grade squamous intraepithelial lesion (HSIL
) (Encompassing: moderate and severe dysplasia, CIS; CIN 2 and CIN 3)
The study group consisted of 55 cases of SCC and 45 cases of HSIL
According to the morphology determined in bioptic samples, cervical findings were characterized as normal findings (non-specific cervicitis); LSIL (cervicitis chronica virosa, flat condyloma, mild dysplasia); HSIL
(moderate dysplasia, severe dysplasia, in situ squamous cell carcinoma) and invasive squamous cell carcinoma .
Among the HSIL
, only 14.29% were positive for p53 overexpression [Figure 2a] while among the LSIL not a single case was positive for p53 overexpression [Figure 2b].
Through these initiatives, we are not only expanding our footprint, but creating a space for our consumers to explore, with our expert help, the perfect fit to their tastes, preferences and lifestyles." said president, building products division, HSIL
, Manish Bhatia.
The cutoff values for LSIL and HSIL
were [greater than or equal to] 3 and [greater than or equal to] 5, respectively [1, 19-21].
Only three Pap smears (1%) yielded a high-grade (HSIL
Cytology often underestimates the grade of ASIL compared with the corresponding biopsy, although the positive predictive value of HSIL
on anal cytology is very high .
National Cancer Institute-funded randomized ANCHOR trial is examining ablative therapy versus watchful waiting in HIV-infected patients with anal HSIL
lesions; however, results of this large study aren't expected until 2022 or 2023.